Pharma channel feed – Endpoints News

Pharma channel feed

Hammered on a gene therapy setback, Dimension cuts staff and circles the wagons

8 years ago

Ariad’s safety woes panicked investors – including staffers with insider info: SEC

8 years ago

Tiny Innate reports a PhIIb disaster, battering shares — and a NY congressman

8 years ago

Pfizer preps new hires as it begins building a $200M R&D campus

8 years ago

FDA OKs Portola’s anticoagulant betrixaban for preventing blood clots

8 years ago

PhIII-focused Cara sees shares spike on its new ‘breakthrough’ status at the FDA

8 years ago

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

8 years ago

The closest thing to a shoo-in Pfizer has ever handed to the FDA just got rejected

8 years ago

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

8 years ago

Top 20 blockbuster drugs in the late-stage pipeline — EvaluatePharma

8 years ago

The small, virtual team at Syntimmune bags a $50M round in the march toward a pivotal test

8 years ago

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

8 years ago

Wobbly Parexel International snapped up for $5B in latest CRO buyout

8 years ago

Several CEOs and 17 years later, Melinta scores an FDA OK for its antibiotic

8 years ago

Massachusetts Governor Charlie Baker unveils a $500M program to keep its big biotech hub booming

8 years ago

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

8 years ago

Novartis wins another biosimilar round with an OK for its Rituxan copycat

8 years ago

EY: Post-boom biotech still has plenty of upbeat trends to boast about

8 years ago

J&J sets out to build a new R&D group after a $1B biotech christening

8 years ago

The myth of “leaner and meaner” pharma

8 years ago

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research

8 years ago

With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now

8 years ago

Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory

8 years ago

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

8 years ago

First page Previous page 323 324 325326327 328 329 Next page Last page